SynthesisNeurosciences (Riyadh, Saudi Arabia)2026
Cerebrovascular and Bleeding Outcomes of Warfarin versus Direct Oral Anticoagulants Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Synthesis in Neurosciences (Riyadh, Saudi Arabia), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To compare the effects on cerebral health in atrial fibrillation patients receiving either warfarin or direct oral anticoagulants (DOACs). Atrial fibrillation is linked to a higher likelihood of both stroke and cognitive impairment. While warfarin has historically served as the leading anticoagulant treatment, DOACs are now more frequently viewed as alternatives with an improved safety profile. Methods: The methodology involved an extensive search of multiple databases, completed up to June 2024. This search yielded randomized controlled trials, which together enrolled over 60,000 participants between the ages of 70 and 84. The DOACs studied were dabigatran, rivaroxaban, apixaban, and edoxaban, given in various dosages. Warfarin was administered with dose adjustments to keep the international normalized ratio within a target range of 2.0 to 3.0. Results: With a relative risk of 0.81 (95% CI, p < 0.00001; I Conclusion: The DOACs are frequently more efficacious than warfarin in avoiding stroke and systemic embolism in patients with non-valvular atrial fibrillation. A significant decline in hemorrhagic stroke was the main cause of the pooled data's 19% relative risk reduction in stroke or systemic embolism. While bleeding outcomes varied among the individual DOACs, the overall findings support their favorable risk-benefit profile. Compared to warfarin, DOACs consistently showed fewer intracranial hemorrhages and a more favorable bleeding profile. These results support prioritizing DOACs in clinical practice, given their enhanced safety and reduced mortality rates. However, due to differences in bleeding risks among DOACs, treatment decisions should be tailored to individual patient factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.